AVITA Medical's PermeaDerm Shows 70% Cost Advantage Over Allograft in Burn Care Study
Event summary
- AVITA Medical's PermeaDerm demonstrated a 70% economic advantage over allograft in a multicenter, randomized controlled study, with a mean cost of $148.70 per %TBSA treated vs. $497.10 for allograft.
- The study showed a 96% reduction in preparation time for PermeaDerm compared to allograft, with comparable clinical outcomes including graft take and wound healing.
- The trial enrolled 40 patients across 11 U.S. burn centers, with all investigators and patients reporting satisfaction at final follow-up.
- AVITA Medical will host a Key Opinion Leader webinar on August 18, 2026, to discuss the PermeaDerm-I clinical data.
The big picture
AVITA Medical's PermeaDerm study results position the biosynthetic wound matrix as a strong alternative to cadaveric allografts in burn care, addressing both economic and clinical needs. The study's findings could drive broader adoption in acute wound care, particularly as healthcare systems seek cost-effective solutions without compromising patient outcomes. The results also strengthen AVITA Medical's portfolio in the competitive wound care market, where innovation in temporary wound coverage is increasingly valued.
What we're watching
- Market Adoption
- How quickly hospitals and burn centers will adopt PermeaDerm given its cost and efficiency advantages over traditional allografts.
- Regulatory Approval
- Whether PermeaDerm will secure additional regulatory approvals beyond the current study, expanding its use cases.
- Competitive Response
- How competitors in the wound care space will react to PermeaDerm's proven economic and clinical benefits.